Produits et services

Organoid culture media for use in scientific research; cell culture media for use in scientific research; biological tissue cultures, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes; reagents for use in biotechnology; cell culture reagents for scientific and research use; biochemicals for in vitro and in vivo scientific use; cells for scientific or laboratory purposes; stem cells, other than for medical or veterinary purposes; protein preparations for scientific or laboratory purposes; diagnostic gene or protein biomarkers for analyzing proteins for scientific or laboratory purposes; chemical preparations for analyses in laboratories, other than for medical purposes; proteins for use in food industry; protein for use in the manufacture of cosmetics.

Abrégé

The present invention relates to a method for evaluating an efficacy of an anticancer drug or an anticancer drug candidate, comprising the step of treating a mixture of cancer organoids and immune cells with the anticancer drug or the anticancer drug candidate. In addition, it relates to the anticancer drug efficacy evaluation system or anticancer drug screening system comprising cancer organoids and immune cells. The present invention relates to a method for evaluating an efficacy of an anticancer drug or an anticancer drug candidate, comprising the step of treating a mixture of cancer organoids and immune cells with the anticancer drug or the anticancer drug candidate. In addition, it relates to the anticancer drug efficacy evaluation system or anticancer drug screening system comprising cancer organoids and immune cells. The mixture of cancer organoids and immune cells according to the present invention is mixed in a specific ratio, and accordingly can similarly reproduce a tumor microenvironment in which cancer cells exist in the body. Therefore, it can make it possible to accurately predict the efficacy of the drug when administered to a subject.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a medium composition for preparing a cancer organoid. In addition, the present invention relates to: a method for preparing a cancer organoid, comprising a step of culturing using the medium composition; and a cancer organoid prepared by the preparation method. A medium for preparing a cancer organoid according to the present invention can promote proliferation of the cancer organoid and maintain stemness of the cancer organoid. Accordingly, the medium can be used to prepare cancer organoids of uniform quality in large quantities within a short period of time, and the cancer organoids prepared with the medium can also be used to directly observe effects on cancer cell proliferation/metastasis and anticancer drug resistance, and can be used in the development of a drug screening platform to check patient-specific anticancer drug resistance in advance. In addition, observation of gene expression regulation according to drug treatment can contribute to the study of molecular mechanisms for the purpose of cancer treatment.

Classes IPC  ?

• C12N 5/09 - Cellules tumorales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a medium composition for preparing a salivary gland organoid. Also, the present invention relates to: a method for preparing a salivary gland organoid, comprising a step of culturing salivary gland-derived cells in the medium composition; and a salivary gland organoid prepared by the preparation method. A medium for preparing a salivary gland organoid, according to the present invention, can promote the proliferation of a salivary gland organoid, maintain the stemness of the salivary gland organoid, and increase engraftment capability. Therefore, the medium can be used to prepare a large amount of salivary gland organoids with excellent quality, and salivary gland organoids prepared using the medium can be used as a preventive or therapeutic agent for salivary gland-related diseases, an alternative to animal experimental models for salivary gland-related diseases, or the like.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61K 35/55 - Glandes non prévues dans les groupes , p. ex. glandes thyroïdes, parathyroïdes ou pinéales
• A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites

Abrégé

2α2α2α2α2α2α2α analogue, according to the present invention, can exhibit the effect of treating or preventing kidney damage caused by antibiotics. Particularly, since the effect can be achieved without influencing the antibacterial effectiveness of antibiotics, the composition can be effectively used as a material for treating, alleviating or preventing kidney diseases.

Classes IPC  ?

• A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs

Produits et services

Organoid culture media for use in scientific research; cell culture media for use in scientific research; biological tissue cultures, other than for medical or veterinary purposes; biological preparations, other than for medical or veterinary purposes; reagents for use in biotechnology; cell culture reagents for scientific and research use; biochemicals for in vitro and in vivo scientific use; cells for scientific or laboratory purposes; stem cells, other than for medical or veterinary purposes; protein preparations for scientific or laboratory purposes; diagnostic gene or protein biomarkers for analyzing proteins for scientific or laboratory purposes; chemical preparations for analyses in laboratories, other than for medical purposes; proteins for use in food industry; protein for use in the manufacture of cosmetics.

Abrégé

The present invention relates to: a method for evaluating the efficacy of an anticancer drug using a mixture of peripheral blood mononuclear cells (PBMCs) and cancer organoids; a method for screening the anticancer drug; a system for evaluating the efficacy of the anticancer drug; or a system for screening the anticancer drug. Specifically, the present invention relates to: a method for evaluating the efficacy of an anticancer drug using a mixture of cytotoxic T cells differentiated from PBMCs and cancer organoids; a method for screening the anticancer drug; a system for evaluating the efficacy of the anticancer drug; or a system for screening the anticancer drug. The method for evaluating the efficacy of an anticancer drug, the screening method, the efficacy evaluation system, or the screening system according to the present invention can very closely reproduce a tumor microenvironment, which is the form in which cancer cells exist in a living body. In addition, since PBMCs derived from a normal individual are used through differentiation into cytotoxic T cells specific to a cancer patient, the burden of collecting biological samples such as blood and tissue samples from the cancer patient can be reduced, and the efficacy of an anticancer drug can be evaluated with high accuracy.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a medium composition for producing nasal mucosal organoids and a method for producing nasal mucosal organoids, the method comprising the step of culturing cells derived from a nasal mucosal tissue in the medium composition. The nasal mucosal organoids produced according to the present invention exhibit high tissue similarity to human nasal mucosal tissues and can be directly infected by viruses such as the coronavirus, or bacteria. Consequently, the method for producing nasal mucosal organoids according to the present invention can be utilized for producing nasal mucosal organoids that closely resemble the morphology and function of biological tissues. Furthermore, the produced nasal mucosal organoids can be beneficially employed for the screening or efficacy evaluation of treatments/vaccines against viral or bacterial infections.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to a method for preparing pancreatic cancer organoids mimicking a cancer microenvironment. In addition, the present invention relates to a method for evaluating the efficacy of pancreatic cancer organoids prepared by the above preparation method and an anticancer agent using the pancreatic cancer organoids, and a screening method. The preparation method according to the present invention can prepare pancreatic cancer organoids that perfectly mimic a cancer microenvironment. Accordingly, the pancreatic cancer organoids prepared by the above method can directly observe the effects on cancer cell proliferation/metastasis and anticancer agent resistance, and can be used to develop a drug screening platform to confirm patient-specific anticancer agent resistance in advance. In addition, observation of gene expression regulation according to drug treatment can contribute to the study of molecular mechanisms for the purpose of cancer treatment.

Classes IPC  ?

• C12N 5/09 - Cellules tumorales
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a medium composition for preparing an intestinal organoid. In addition, the present invention relates to: a method for preparing an intestinal organoid, comprising a step of culturing using the medium composition; and an intestinal organoid prepared by the preparation method. The medium for preparing an intestinal organoid can promote the proliferation of the intestinal organoid and maintain the stemness of the intestinal organoid. Therefore, the medium can be used in preparing a large amount of intestinal organoids of excellent quality, and intestinal organoids prepared using the medium can be used as agents for preventing or treating intestine-associated diseases, alternatives to animal experimental models of intestine-associated diseases, and the like.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61K 35/38 - EstomacIntestinCellules caliciformesMuqueuse oraleSalive
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse

Abrégé

The present invention relates to a lacrimal gland organoid preparation method. In addition, the present invention relates to: a lacrimal gland organoid prepared by the preparation method; a formulation for preventing or treating dry eye disease, the formulation including the lacrimal gland organoid; and a method for screening a material for preventing or treating dry eye disease using the lacrimal gland organoid. The lacrimal gland organoid prepared according to the present invention has high tissue similarity with human lacrimal gland tissue and excellent tear secretion ability, and in particular, can regenerate damaged lacrimal gland tissue to normalize tear secretion ability when transplanted in vivo. Accordingly, the lacrimal gland organoid preparation method according to the present invention can be used to prepare a lacrimal gland organoid that is similar in shape and function to living tissue, and the prepared lacrimal gland organoid can be used as a material for treating dry eye disease such as Sjogren's syndrome or corneal xerosis or effectively utilized as a method for screening a material for treating dry eye syndrome.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• A61K 35/24 - MucusGlandes des muqueusesBoursesLiquide synovialLiquide articulaireExcretaLiquide céphalorachidien
• A61P 27/02 - Agents ophtalmiques
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present disclosure relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease, comprising an intestinal organoid and a TNFα inhibitor. The combination use of the intestinal organoid and TNFα inhibitor according to the present disclosure can alleviate symptoms of inflammatory bowel disease such as weight loss, diarrhea, and bloody stool, and can inhibit fibrosis of the intestinal mucosa due to inflammation. In particular, when the intestinal organoid and the anti-inflammatory TNFα inhibitor are used in combination, the therapeutic effect is significantly superior to that of multiple administrations of the TNFα inhibitor, and thus it can be usefully used as an agent for preventing or treating inflammatory bowel disease.

Classes IPC  ?

• A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c.-à-d. autres que des liaisons 3'-5' phosphodiester
• A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

The present invention relates to a composition comprising an inhibitor of herpesvirus entry mediator (HVEM) or its ligand and a heat shock protein (HSP) inhibitor for treating or preventing cancer. The use of an inhibitor of HVEM or its ligand and an HSP inhibitor in combination exhibits a synergistic effect on anticancer activity, compared to the use thereof singly, and shows an effect within as fast as 72 hours after administration. Therefore, the use of an inhibitor of HVEM or its ligand and an HSP inhibitor in combination can be advantageously utilized for preventing or treating cancer.

Classes IPC  ?

• A61K 39/42 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire viraux
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p. ex. adénosine, acide adénylique
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a method for evaluating efficacy of an anticancer agent or an anticancer agent candidate, the method comprising a step of treating a mixture of a cancer organoid and immune cells with an anticancer agent or an anticancer agent candidate. In addition, the present invention relates to a system comprising a cancer organoid and immune cells for evaluating the efficacy of an anticancer agent or screening an anticancer agent. With a specific mixing ratio, the mixture of a cancer organoid and immune cells according to the present invention can mimic a tumor microenvironment under which cancerous cells exist in vivo. Therefore, when utilized, the mixture allows for the accurate prediction of the efficacy of a drug administered in vivo.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, the pharmaceutical composition comprising an intestinal organoid and a TNFα inhibitor. The combined use of the intestinal organoid and the TNFα inhibitor, according to the present invention, can alleviate symptoms of inflammatory bowel disease, such as weight loss, diarrhea, and bloody stool, and can inhibit fibrosis of the intestinal mucosa caused by inflammation. In particular, when the intestinal organoid and the TNFα inhibitor, which is an anti-inflammatory agent, are used in combination, a significantly superior therapeutic effect can be exhibited as compared to when the TNFα inhibitor is administered multiple times, and thus, the intestinal organoid and the TNFα inhibitor can be effectively used as substances for preventing or treating inflammatory bowel disease.

Classes IPC  ?

• A61K 35/38 - EstomacIntestinCellules caliciformesMuqueuse oraleSalive
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif

Abrégé

The present invention relates to a composition for transplantation comprising an organoid, and a use of same. According to one example, using collagen, gelatin or fibrin glue as a scaffold for organoid transplantation results in a high transplantation rate and a high survival rate of organoid as well as desirable stability.

Classes IPC  ?

• A61L 27/22 - Polypeptides ou leurs dérivés
• A61L 27/24 - Collagène
• A61L 27/26 - Mélanges de matériaux macromoléculaires
• A61L 27/38 - Cellules animales

Abrégé

As a tonsilar organoid preparation method and a use thereof, provided are a tonsilar organoid preparation medium and preparation method, the medium additionally comprising a hepatocyte growth factor (HGF) in TFM while not comprising 4-[4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol, and thus tonsilar organoids exhibiting the same physiological activity as that of real tonsilar tissue can be long-term subcultured.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Produits et services

Conducting early evaluations in the field of new pharmaceuticals; development, analysis and evaluation of medical product; drug discovery services; conducting clinical trials; conducting clinical trials for others; platform as a service; development of implants comprising living tissue; development of cell therapy products; development of cell culture medium; biotechnology services; design services relating to process systems for the biotechnology industry; consultancy in the field of testing, inspection, research of medical products; research and development of new products; materials testing and evaluation; conducting technical project studies; engineering testing; scientific research in the fields of medicine, health and pharmacology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs.

Produits et services

Conducting early evaluations in the field of new pharmaceuticals; development, and quality evaluation of medical product; drug discovery services; development of implants comprising living tissue; development of cell therapy products; development of cell culture medium; design services relating to process systems for the biotechnology industry, namely, design and development of new technology for others in the field of biotechnology; consultancy in the field of testing, inspection, research of medical products; research and development of new products; materials testing and evaluation; conducting technical project studies in the field of biotechnology; scientific research in the fields of medicine, health and pharmacology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs

Abrégé

The present invention relates to a composition for culturing organoids and a method for culturing organoids by using the same. Since the present invention includes a compound, which can replace an essential protein component in a conventional medium, consistent stability during organoid culturing can be maintained and culturing can be performed at low cost.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C07D 473/10 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 deux atomes d'oxygène avec des radicaux contenant uniquement des atomes d'hydrogène et de carbone, liés en position 1 ou 3 avec des radicaux méthyle en positions 3 et 7, p. ex. théobromine

Abrégé

The present invention relates to a composition for transplantation comprising an organoid, and a use of same. According to one example, using collagen, gelatin, or fibrin glue as a scaffold for organoid transplantation results in a high transplantation rate and a high survival rate of the organoid as well as desirable stability.

Classes IPC  ?

• A61L 27/38 - Cellules animales
• A61L 27/26 - Mélanges de matériaux macromoléculaires
• A61L 27/22 - Polypeptides ou leurs dérivés
• A61L 27/24 - Collagène